Abstract Metformin is an effective agent with a good safety profile that is widely used as a first-line treatment for type 2 diabetes, yet its mechanisms of action and variability in terms of efficacy and side effects remain poorly understood
Three branded semaglutide products currently exist: Ozempic (injection, 0.25 mg to 2 mg weekly) for type 2 diabetes and cardiovascular risk reduction Wegovy (injection, up to 2.4 mg weekly) for long-term weight management in obese or overweight adults Rybelsus (oral tablet, 3 mg to 14 mg daily) for type 2 diabetes Compounded semaglutide, which some U.S
or symptoms of severe dehydration such as decreased urination, dizziness, or confusion
Genolet R, Wahli W, Michalik L (2004) PPARs as drug targets to modulate inflammatory responses
It suggested that epithalon might have the ability to prolong the lifespan of individual cells or whole organisms [9]